Company news
Aprea Therapeutics, Inc. (NASDAQ:APRE) news
Aprea Therapeutics, Inc. news releases on 6ix. Latest, Aug 10, 2023: Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update…
Press releases — page 2
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
August 9, 2023
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
May 14, 2023
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
May 7, 2023
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
March 29, 2023
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
February 26, 2023
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
February 21, 2023
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
February 21, 2023
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
February 14, 2023
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
February 12, 2023
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
January 29, 2023
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
January 10, 2023
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
November 8, 2022
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
September 21, 2022
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
August 10, 2022
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
May 15, 2022
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
March 14, 2022
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
December 12, 2021
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
December 8, 2021
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
November 7, 2021
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
August 11, 2021
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
August 4, 2021
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
July 20, 2021
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
June 15, 2021
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
May 5, 2021
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
April 15, 2021
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
April 7, 2021
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
March 15, 2021
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
December 27, 2020
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
November 29, 2020
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
November 4, 2020
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
October 13, 2020
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
October 6, 2020
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
September 28, 2020
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
September 17, 2020
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
August 10, 2020
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
July 15, 2020
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
June 28, 2020
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
June 2, 2020
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
May 14, 2020
Aprea Therapeutics Launches New Corporate Website - www.aprea.com
April 5, 2020
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 25, 2020
Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial
February 12, 2020
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
January 29, 2020
Aprea Therapeutics Reports Third Quarter 2019 Financial Results
November 13, 2019
Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 6, 2019
Aprea Therapeutics Announces Pricing of Initial Public Offering
October 1, 2019